Axcella Health is a clinical-stage biotechnology company focused on an approach to treat diseases using compositions of endogenous metabolic modulators. Co.'s pipeline includes main therapeutic candidates for the treatment of Long COVID associated fatigue, and for the treatment of non-alcoholic steatohepatitis (NASH). AXA1125 is being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy recurrence in adult patients with liver cirrhosis. The AXLA average annual return since 2019 is shown above.
The Average Annual Return on the AXLA average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AXLA average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AXLA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|